BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1 tyrosine kinase inhibitors (TKIs). The third-generation ABL1 TKI ponatinib is effective against BCR-ABL1 point mutants individually, but remains vulnerable to certain BCR-ABL1 compound mutants. To determine the f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Khorashad, Jamshid S., Kelley, Todd W., Szankasi, Philippe, Mason, Clinton C., Soverini, Simona, Adrian, Lauren T., Eide, Christopher A., Zabriskie, Matthew S., Lange, Thoralf, Estrada, Johanna C., Pomicter, Anthony D., Eiring, Anna M., Kraft, Ira L., Anderson, David J., Gu, Zhimin, Alikian, Mary, Reid, Alistair G., Foroni, Letizia, Marin, David, Druker, Brian J., O'Hare, Thomas, Deininger, Michael W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2013
Schlagworte:
Myeloid Neoplasia
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548169/
https://ncbi.nlm.nih.gov/pubmed/23223358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-431379
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge